Alnylam Pharmaceuticals, Inc. Announces Retirement of Laurie B. Keating as Executive Vice President, Chief Legal Officer and Secretary, Effective on September 10, 2021
September 08, 2021 at 08:36 am EDT
Share
On September 6, 2021, Laurie B. Keating, a named executive officer of Alnylam Pharmaceuticals, Inc., retired from the company and resigned from her position as Executive Vice President, Chief Legal Officer and Secretary of the company, effective September 10, 2021, following 7 years of service.
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Alnylam Pharmaceuticals, Inc. Announces Retirement of Laurie B. Keating as Executive Vice President, Chief Legal Officer and Secretary, Effective on September 10, 2021
ALNYLAM PHARMACEUTICALS, INC. 
